Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 9
Submit an article Journal homepage
61
Views
9
CrossRef citations to date
0
Altmetric
Review

Prevention of perinatal HIV transmission: a review of novel strategies

Athena P Kourtis 540 Wembley Circle, Atlanta, GA 30328, USA. [email protected]
&
Ann Duerr 540 Wembley Circle, Atlanta, GA 30328, USA. [email protected]
Pages 1535-1544 | Published online: 02 Mar 2005

Bibliography

  • MANDELBROT L, LECHENADEC J, delivery in the French Perinatal Cohort. JAMA (1998) 280:55–60.
  • LALLEMANT M, JOURDAIN G, LE COEUR S et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus Type 1. N Engl. Med. (2000) 343:982–991.
  • KIND C, RUDIN C, SIEGRIST CA et Prevention of vertical HIV transmission: additive protective effect of elective cesareansection and zidovudine prophylaxis. AIDS (1998) 12:205–210.
  • WORKING GROUP ON MOTHER-TO-CHILD TRANSMISSION OF HIV: Rates of mother-to-child HIV in Africa, America and Europe: results from 13 perinatal studies. I AIDS Hum. Retrovirol. (1995) 8:506–510.
  • DECOCK KM, FOWLER MG, MERCIER E et al: Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 283:1175–1182.
  • ARBONA SI, MELVILLE SK, HANSON C et al.: Mother-to-child transmission of the human immunodeficiency virus in Texas. Pediatr. Infect. Dis. (2001) 20:602–606.
  • DECOCK K: Heterogeneity and Public Health in the Global HIV/AIDS Epidemic Top. HIV Med. (2001) 9(3):15–19.
  • CONNOR EM, SPERLING R, GELBER R et al: Reduction of maternal-infant transmission of HIV Type 1 with zidovudine treatment. N Engl. J. Med. (1994) 311:1173–1180.
  • •Seminal first trial that showed efficacy of zidovudine in reducing perinatal transmission of HIV-1.
  • SPERLING RS, SHAPIRO ED, COOMBS RW et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of HIV-1 from mother to infant. N Engl. J. Med. (1996) 335:1621–1629.
  • BLANCHE S, TARDIEU M, RUSTIN P et al: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet (1999) 354:1084–1089.
  • PERINATAL SAFETY REVIEW WORKING GROUP: Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs. J. Acquit: Immune Defic. Syndr: (2000) 15:261–268.
  • SHIRAMIZU B, SHIKUMA KM, KAMEMOTO L et al.: Brief report: placenta and cord blood mitochondrial DNA toxicity in HIV-1 infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. I Acquir: Immune Defic. Syndr: (2003) 32:370–374.
  • EASTMAN PS, SHAPIRO DE, COOMBS RW et al.: Maternal viral genotypic resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of HIV-1 in pediatric AIDS Clinical Trials Group../. Infect. Dis. (1998) 177:557–564.
  • PALUMBO P, HOLLAND B, DOBBS T et al.: Antiretroviral resistance mutations among pregnant human immunodeficiency virus type-1 infected women and their newborns in the United States: vertical transmission and clades. J. Infect. Dis. (2001) 184:1120–1126.
  • WELLES SL, PITT J, COLGROVE R et al.: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS (2000) 14:263–271.
  • COOPER ER, NUGENT RP, DIAZ C et al: After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of HIV in a cohort of infected women and their infants. Infect. Dis. (1996) 174:1207–1211.
  • MATHESON PB, ABRAMS EJ, THOMAS PA et al: Efficacy of antenatal zidovudine in reducing perinatal transmission of HIV-1. J. Infect. Dis. (1995) 172:353–358.
  • EUROPEAN COLLABORATIVE STUDY: HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS(2001) 15:761–770.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR (2002) 51 (RR18):1–38.
  • ••Comprehensive review of pharmacologyand current guidelines for prevention of HIV-1 transmission strategies from mother to infant.
  • SHAFFER N, CHUACHOOWONG R, MOCK P et al.: Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet (1999) 353:773–780.
  • WIKTOR S, EKPINI E, KARON J et al.: Short-course oral zidovudine for prevention of mother to child tranmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet (1999) 353:781–785.
  • DABIS F, MSELLATI P, MEDA N etal.: 6 month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double blind placebo controlled multicentre trial. Lancet (1999) 353:786–792.
  • LEROY V, NEWELL ML, DABIS F etal.: International multicentre pooled analysis of late postnatal mother to child transmission of HIV-1 infection. Lancet (1998) 352:597–600.
  • FISCUS S, ADIMORA A, SCHOENBACH V et al: Trends in HIV counseling, testing and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J. Infect. Dis. (1999) 180(1):99–105.
  • WADE N, BIRKHEAD G, WARREN B et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. (1998) 339:1409–1414.
  • WADE NA, BIRKHEAD GS, WARREN BL et al.: Short courses of zidovudine and perinatal transmission of HIV (letter). N Engl. J. Med. (1999) 340:1042–1043.
  • BULTERYS M, ORLOFF S, ABRAMS E et al.: for the Perinatal AIDS Collaborative Transmission Study. Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: A prospective cohort study in 4 US cities. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants Montreal, Canada (1999) (Abstract 015).
  • BARDSLEY-ELLIOT A, PERRY CM: Nevirapine: A review of its use in the prevention and treatment of paediatric HIV infection. Paediatr. Drugs (2000) 5:373–407.
  • GUAY L, MUSOKE P, FLEMING T et al: Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet (1999) 354(9181):795–801.
  • •Important trial showing efficacy of a very simple nevirapine regimen.
  • MOODLEY D, MOODLEY J, COOVADIA H et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of HIV-1. J. Infect. Dis. (2003) 187:725–735.
  • DORENBAUM A, CUNNINGHAM CK, GELBER RD et al.: Two-dose intrapartum/ newborn nevirapine and standard antiretroviral thepapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA (2002) 288:189–198.
  • ESHLEMAN SH, MRACNA M, GUAY LA et al: Selection and fading of resistance mutations in women and infants 1542 Expert Op/n. lnvestig. Drugs (2003) 12(9) receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 15:1951–1957.
  • CUNNINGHAM CK, CHAIX ML, REKACEWICZ C et al.: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal HIV-1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. Infect. Dis. (2002) 186:181–188.
  • STRINGER JS, SINKALA M, STOUT JP et al.: Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (2003) 32:506–513.
  • THE PETRA STUDY TEAM: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet (2002) 359:1178–1186.
  • MANDELBROT L, LANDREAU-MASCARO A, REKACEWICZ C et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA (2001) 285:2083–2093.
  • CLARKE JR, BRAGANZA R, MIRZA A et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. I Med. Virol. (1999) 59:364–368.
  • DABIS F, LEROY V, BEQUET L et al.: Effectiveness of a short course of zidovudine + nevirapine to prevent mother to child transmission (PMTCT) of HIV-1: The Ditrame Plus, ANRS 1201 Project in Abidjan, Cote d'Ivoire. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract 1428).
  • HELFGOTT AW, ERIKSEN N, LEWIS S et al: Highly active antiretroviral therapy for the prevention of perinatal HIV. Am.j Obstet. Cynecol. (2000) (Suppl., Part 2):100 (Abstract).
  • BLATTNER W, COOPER E, CHARURAT M et al.: Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV-1. XIII International AIDS Conference, Durban, South Africa (2000) (Abstract LbOr4).
  • BRYSON Y, STEK A, MIROCHNICK M et al.: Pharmacokinetics, antiviral activity, and safety of nelfinavir (NFV) with ZDV/ 3TC in pregnant HIV-1 infected women and their infants: PACTG 353 Cohort 2. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA (2002) (Abstract 795–W).
  • THE EUROPEAN COLLABORATIVE STUDY AND THE SWISS MOTHER CHILD HIV COHORT STUDY: Combination antiretroviral therapy and duration of pregnancy. AIDS(2000) 14:2913–2920.
  • SHAPIRO D, TUOMALA R, SAMELSON R et al.: Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-infected women in 1998–1999 (PACTG 367). 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2000) (Abstract 664).
  • JUNGMANN EM, MERCEY D, DERUITER A et al.: Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm. Infect. (2001) 77:441–443.
  • MANDELBROT L, MSELLATI P, MEDA N et al.: 15 month follow up of African children following vaginal cleansing with benzalconium chloride of their HIV-1 infected mothers during late pregnancy and delivery. Sex Transm. Infect. (2002) 78:267–270.
  • BIGGAR RJ, MIOTTI PG, TAHA TE et al.: Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV-1 transmission. Lancet (1996) 347: 1647-1650.
  • GAILLARD P, MWANYUMBA F, VERHOFSTEDE C et al.: Vaginal lavage with chlorhexidine during labour to reduce mother to child HIV-1 transmission: clinical trial in Mombasa, Kenya. AIDS (2001) 15:389–396.
  • FAWZI WW, MSAMANGA GI, HUNTER D et al.: Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS(2002) 16: 1935-1944.
  • STOLZFUS RJ, HUMPHREYS JH: Vitamin A and the nursing mother-infant dyad: evidence for intervention. Adv. Exp. Med. Biol. (2002) 503:39–47.
  • PILLAY C, GRAY G, STEVENS G et al.:Emergence of resistance mutations in children treated with ddI plus d4T after treatment to prevent mother to child transmission. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract B4583).
  • ZORILLA CD, VAN DYKE R, BARDEGUEZ A et al.: Clinical response, safety, and tolerability to saquinavir-SCG with low-dose ritonavir boosting in combination with zidovudine and lamivudine in HIV-1 infected pregnant women: preliminary results of PACTG 386. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 887).
  • SCOTT G, RODMAN J, SCOTT W et al.: Pharmacokinetics and virologic response to ritonavir in combination with zidovudine and lamivudine in HIV-1 infected pregnant women and their infants. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA (2002) (Abstract 794–W).
  • LALLEMANT MC, THAINEUA V, JOURDAN G et al.: PHPT-2: Nevirapine plus zidovudine for the prevention of perinatal HIV-1. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract C10914).
  • SILVERMAN MS, THISTLE P, ARBESS G et al: Superiority of an 'ultra-short' zidovudine regimen in the prevention of perinatal HIV-1 transmission in rural Zimbabwe. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract D3680).
  • SAEZ-LLORENS X, VIOLARI A, DEETZ CO et al.: Forty-eight week evaluation of lopinavir/ritonavir, a new protease inhibitor, in HIV-1 infected children. Pediatr. Infect. Dis. I (2003) 22:216–224.
  • LALEZARI JP, HENRY K, O'HEARN Met al: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV-1 infection in North and South America. N Engl. Med. (2003) 348:2175–2185.
  • VAN ROMPAY K, MILLER MD, MARTHAS ML et al: Prophylactic and therapeutic benefits of short-term 9- [2-(R)-(phosphonomethoxy)propylladenine (PMPA) administration to newborn macaques following oral inoculation with SIV with reduced susceptibility to PMPA. Virol. (2000) 74:1767–1774.
  • DEEKS S, BARDITCH-CROVOP, LIETMAN P et al.: Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(A)-(phosphonomethoxy)propylladenine, a novel anit-HIV-1 therapy, in HIV-1-1543 infected adults. Antimicrob. Agents Cliemother. (1998) 42:2380–2384.
  • BARDITCH-CROVO P, DEEKS SG, COLLIER A et al: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob. Agents Cliemother. (2001) 45:2733–2739.
  • PALMER S, MARGOT N, GILBERT H et al.: Tenofovir, adefovir, and zidovudine susceptibilities of primary HIV-1 isolates with non-B subtypes or nucleoside resistance. AIDS Res. Hum. Retrovjruses (2001) 17:1167–1173.
  • TARANTAL AF, MARTHAS ML, SHAW JP et al.: Administration of 9-[2-(R)-(phosphonomethoxy)propyll adenine (PMPA) to gravid and infant rhesus macaques (macaca mulatta): safety and efficacy studies. I Acquir: Immune Defic. Syndr: Hum. Retrovirol (1999) 20:323–333.
  • MIOTTI PG, TAHA TE, KUMWENDA N et al: HIV transmission through breastfeeding. A study in Malawi. JA/VIA (1999) 282:744–749.
  • NDUATI RW, JOHN GC, RICHARDSON BA et al.: HIV-1 infected cells in breast milk: association with immunosuppression and vitamin A deficiency." Infect. Dis. (1995) 172:1461–1468.
  • COUTSOUDIS A, PILLAY K, KUHN L et al.: Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS(2001) 15:379–387.
  • FOWLER MG, NEWELL ML: Breast-feeding and HIV-1 transmission in resource-limited settings." Acquir. Immune Defic. Syndr. Hum. Retrovirol (2002) 30:230–239.
  • •Comprehensive review of breastfeeding transmission of HIV-1.
  • SAVARINO A, GENNERO L, CHEN HC et al.: Anti-HIV-1 effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS (2001) 23:2221–2229.
  • BOELAERT JR, YARO S, AUGUSTIJNS P et al.: Chloroquine accumulates in breast milk cells: potential impact in the prophylaxis of postnatal mother to child transmission of HIV-1. AIDS (2001) 15:2205–2207.
  • SEMBA RD, KUMWENDA N, HOOVER DR et al: HIV load in breast milk, mastitis, and mother-to-child transmission of HIV Type 1.1 Infect. Dis. (1999) 180:93–98.
  • BORKOWSKY W: Immunotherapy for pregnant women and newborns. Ann. NY Acad. Sci. (2000) 918:313–317.
  • WRIGHT PF, LAMBERT JS, GORSE GJ et al: Immunization with envelope MN rgp 120 vaccine in HIV-infected pregnant women." Infect. Dis. (1999) 180:1080–1085.
  • FERRANTELLI F, HOFMANN-LEHMANN R, RASMUSSEN R et al: Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV 89.6P infection or disease in neonatal macaques. AIDS (2003) 17:301–309.
  • WATANABE ME: Sceptical scientists skewer VaxGen statistics. Nat. Med. (2003) 9:376.
  • JOHNSON D, MCFARLAND E, MURESAN P et al.: PACTG 326: A Phase I/II study to evaluate the safety and immunogenicity of Alvac HIV-1 vaccines alone and with AIDSVax B/B in children born to HIV-1-infected mothers: preliminary results. 10th Conference on Retro viruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 404).
  • MCFARLAND E, JOHNSON D, FENTON T et al: A Phase I/II study of the safety and immunogenicity of an HIV-1-1 ALVAC vaccine in infants born to HIV-1-infected mothers. 10th Conference on Retro viruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 99).
  • SUSMAN E: Vaccine trials begin. Notes and quotes. AIDS(2003) 17:N5.
  • CHUACHOOWONG R, SHAFFER N, VANCOTT TC et al: Lack of association between human HIV antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in Thailand. Infect. Dis. (2000) 181:1957–1963.
  • STIEHM ER, LAMBERT JS, MOFENSON LM et al: Efficacy of zidovudine and HIV hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease : results of Pediatric AIDS Clinical Trials Group protocol 185. J. Infect. Dis. (1999) 179:567–575.
  • GUAY LA, MUSOKE P, HOM DL et al.:Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS (2002) 16:1391–1400.
  • SHEARER WT, DULIEGE AM, KLINE MW et al.: Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146. Clin. Diag. Lab. Immunol (1995) 2:281–285.

Websites

  • http://www.hptn.org/research_studies/ study_details.asp?Protoco1+%23=HIVNET +024 HIVNET 024: Phase III trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. HPTN study details (2003).
  • http://pactg.s-3.com SPECTOR S: Presentation of PACTG Winter 2002 meeting (2003).
  • http://www.iavi.org/iavireport/0103/ babies.htm INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) REPORT: Are babies in a blind spot? Pediatric workshop highlights barriers to neonatal HIV vaccine development (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.